Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167637 | 1.00 | HSD17B10 (0.42) | HSD17B10PDCD1CD274OPRK1OPRM1 | |
| SCHEMBL873557 | 1.00 | HSD17B10 (0.42) | HSD17B10PDCD1CD274OPRK1OPRM1 | |
| SCHEMBL29108930 | 0.88 | ALDH1A1 (0.50) | HSD17B10ALDH1A1 | |
| SCHEMBL17714037 | 0.86 | HSD17B10 (0.45) | HSD17B10ALDH1A1 | |
| SCHEMBL167007 | 0.86 | HSD17B10 (0.50) | HSD17B10KCNA3ALDH1A1 | |
| SCHEMBL2562032 | 0.81 | — | — | |
| SCHEMBL12635248 | 0.81 | PDCD1 (0.38) | PDCD1CD274OPRK1OPRM1OPRD1 | |
| SCHEMBL5270962 | 0.81 | PDCD1 (0.38) | PDCD1CD274OPRK1OPRM1OPRD1 | |
| SCHEMBL1006087 | 0.81 | KDM4E (0.45) | PDCD1CD274OPRK1OPRM1OPRD1 | |
| SCHEMBL5255963 | 0.81 | KDM4E (0.45) | PDCD1CD274OPRK1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| US-9403830-B2 | Inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| US-9403830-B2 | Inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-8927546-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-01-06 | — | — | US | disclosed |
| US-20140031339-A1 | INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20140031339-A1 | INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| EP-2643000-A2 | THERAPEUTIC PIPERAZINES | Dart Neuroscience (Cayman) Ltd (KY) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012040258-A2 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | disclosed |
| US-20100022531-A1 | NOVEL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-5034402-A | Cerebral insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1991-07-23 | — | — | US | disclosed |
| US-4650878-A | CEREBRAL INSUFFICIENCY | HOFFMANN-LA ROCHE INC. (US) | 1987-03-17 | — | — | US | disclosed |
| US-4476308-A | 1-Pyrrolidine acetamides | HOFFMANN-LA ROCHE INC. (US) | 1984-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | HSD17B10 2919/4885PDCD1 3658/4885CD274 4061/4885 |
| US-20140031339-A1 | INHIBITORS OF LEUKOTRIENE PRODUCTION | LTA4H, LTB4R, LTB4R2 | HSD17B10 311/4885PDCD1 4637/4885CD274 3302/4885 |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | HSD17B10 2919/4885PDCD1 3658/4885CD274 4061/4885 |
| US-20100022531-A1 | NOVEL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | P2RX3, P2RX7, P2RX1 | HSD17B10 4525/4885PDCD1 4306/4885CD274 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.